NanoMAb®

Next generation mAb therapeutics with high affinity, low immunogenicity, excellent stability, and various combination options

  • Conventional mAb
  • Camelid heavy chain mAb
Conventional mAb NanoMAb®
Mechanism ADCC, Neutralization, Agonist
Affinity Kd 10-9 ~10-12M
Origin Murine, human Camelid
Immunogenicity Minimized by humanization High homology to humans
*safety verified
Structure Heavy and light chains Heavy chain only
Size 150 kDa 10 ~ 15 kDa
Solubility of ADC Low High
Multi-targeting Max. 4 Max. 7
pK profile Fixed Controllable

Novel modular protein drug platform with a variety of interacting domains and functional domains suited
for diverse therapeutic purposes, which is highly homologous to human IgG.

Sequence homology between NanoMAb® clone and 15 human VH3